Drug approved by the FDA
for the treatment of Duchenne.
CureDuchenne was an early funder.
CureDuchenne funded research projects
have advanced to human clinical trials
Our lives were changed forever…
“We didn’t know anything about Duchenne and felt isolated that there was no one we could turn to… CureDuchenne has hosted several workshops that have been invaluable in providing knowledge on the care, treatment and future of our son, but, even more importantly, has enabled us to spend time with other Duchenne families…”
Duchenne is a devastating muscle disease.
It’s the most common and severe form of muscular dystrophy. Those affected with Duchenne lose their ability to walk, feed themselves, breath independently and succumb to heart failure. But there’s hope through new pharmacological and gene-based therapies. You can help make a difference.
LOS ANGELES, April 25, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced positive top-line results from a safety and exploratory efficacy analysis of six-month data from the randomized 12-month Phase I/II HOPE Clinical Trial of CAP-1002 (allogeneic cardiosphere-derived cells), an […]
CURE DUCHENNE NEWS
NEWPORT BEACH, Calif., April 5, 2017 – CureDuchenne, the leading nonprofit focused on finding a cure for Duchenne muscular dystrophy, is proud to sponsor SB 643 (Pan) which passed the Senate Health Committee today with a vote of 8-0. SB 643 will add Duchenne to the Genetically Handicapped Persons Program’s (GHPP) list of eligible medical […]